aTyr Pharma Statistics
Total Valuation
aTyr Pharma has a market cap or net worth of $15.56 million. The enterprise value is -$22.27 million.
| Market Cap | 15.56M |
| Enterprise Value | -22.27M |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
aTyr Pharma has 2.55 million shares outstanding. The number of shares has increased by 10.03% in one year.
| Current Share Class | 2.55M |
| Shares Outstanding | 2.55M |
| Shares Change (YoY) | +10.03% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 0.34% |
| Owned by Institutions (%) | 27.67% |
| Float | 2.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.32.
| Current Ratio | 3.05 |
| Quick Ratio | 3.00 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -93.68% and return on invested capital (ROIC) is -50.97%.
| Return on Equity (ROE) | -93.68% |
| Return on Assets (ROA) | -41.98% |
| Return on Invested Capital (ROIC) | -50.97% |
| Return on Capital Employed (ROCE) | -128.98% |
| Weighted Average Cost of Capital (WACC) | 5.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$888,733 |
| Employee Count | 60 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.88% in the last 52 weeks. The beta is 1.05, so aTyr Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -78.88% |
| 50-Day Moving Average | 10.32 |
| 200-Day Moving Average | 23.07 |
| Relative Strength Index (RSI) | 37.35 |
| Average Volume (20 Days) | 108,936 |
Short Selling Information
| Short Interest | 10.27M |
| Short Previous Month | 12.89M |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | -35.40M |
| Operating Income | -55.91M |
| Pretax Income | -53.32M |
| Net Income | -53.32M |
| EBITDA | -55.24M |
| EBIT | -55.91M |
| Earnings Per Share (EPS) | -$21.74 |
Balance Sheet
The company has $48.75 million in cash and $10.92 million in debt, with a net cash position of $37.83 million or $14.84 per share.
| Cash & Cash Equivalents | 48.75M |
| Total Debt | 10.92M |
| Net Cash | 37.83M |
| Net Cash Per Share | $14.84 |
| Equity (Book Value) | 33.79M |
| Book Value Per Share | 13.53 |
| Working Capital | 33.69M |
Cash Flow
In the last 12 months, operating cash flow was -$54.54 million and capital expenditures -$279,000, giving a free cash flow of -$54.82 million.
| Operating Cash Flow | -54.54M |
| Capital Expenditures | -279,000 |
| Depreciation & Amortization | 670,000 |
| Net Borrowing | -562,000 |
| Free Cash Flow | -54.82M |
| FCF Per Share | -$21.50 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
aTyr Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.03% |
| Shareholder Yield | -10.03% |
| Earnings Yield | -356.10% |
| FCF Yield | -352.24% |
Analyst Forecast
The average price target for aTyr Pharma is $45.17, which is 639.89% higher than the current price. The consensus rating is "Hold".
| Price Target | $45.17 |
| Price Target Difference | 639.89% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 125.28% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on October 29, 2026. It was a reverse split with a ratio of 1:40.
| Last Split Date | Oct 29, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
aTyr Pharma has an Altman Z-Score of -15.94. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.94 |
| Piotroski F-Score | n/a |